Partnering: pharma needs biotech
Oxford – Partnering is one of the most important issues for biotech companies, and according to a recent Nature Biotech article (2007, Czerepak et. al.) pharma is becoming more and more dependent on innovations made in biotech. Of the 103 US FDA approvals from January 2006 to December 2007, 45% were granted to biotech companies. A further 16% stem from biotech-pharma partnerships. Only 39% were granted to pharmaceutical companies alone. “This fact makes partnering meetings more and more important”, says Jon Rees, network director of Oxfordshire Bioscience, who is organising the BioTrinity conference taking place on April 15th-16th in Oxford. “Last year, we organized 500 partnering meetings and brought together more than 400 delegates from nearly 300 companies”, says Rees.